European Medicines Agency (EMA) Continues Marketing Authorization Application (MAA) Review for Lymphoseek® Dec 19, 2013
Navidea Biopharmaceuticals Submits Supplemental New Drug Application (sNDA) for Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer Dec 17, 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek® for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer Dec 10, 2013
Navidea Biopharmaceuticals Initiates Pivotal Phase 3 Registration Program of NAV5001 SPECT Imaging Agent for Parkinson’s Disease Dec 3, 2013
Navidea to Collaborate with University of Alabama–Birmingham on Clinical Study Evaluating the RIGS™ Monoclonal Antibody Targeting Agent Nov 26, 2013
